

RESEARCH

Open Access



Health-related quality of life in a european sample of adults with early-treated classical PKU

Stephanie Maissen-Abgottspou¹, Raphaela Muri^{1,2}, Michel Hochuli¹, Péter Reismann³, András Gellért Barta³, Ismail Mucabit Alptekin⁴, Álvaro Hermida-Ameijeiras⁵, Alessandro P. Burlina⁶, Alberto B. Burlina⁷, Chiara Cazzorla⁷, Jessica Carretta⁶, Roman Trepp^{1†} and Regula Everts^{1,8*†} 

Abstract

Background Phenylketonuria (PKU) is a rare inborn error of metabolism affecting the catabolism of phenylalanine (Phe). To date, findings regarding health-related quality of life (HRQoL) in adults with early-treated classical PKU are discrepant. Moreover, little is known about metabolic, demographic, and cognitive factors associated with HRQoL. Hence, we aimed to investigate HRQoL and its association with demographic, metabolic, and cognitive characteristics in a large European sample of adults with early-treated classical PKU.

Results This cross-sectional study included 124 adults with early-treated classical PKU from Hungary, Italy, Spain, Switzerland, and Turkey. All participants prospectively completed the PKU quality of life questionnaire (PKU-QoL), a questionnaire specifically designed to evaluate the impact of PKU and its treatment on HRQoL in individuals with PKU. In addition, information about Phe levels (concurrent and past year), demographic (age and sex), and cognitive variables (intelligence quotient, IQ) were collected. Most domains revealed little or no impact of PKU on HRQoL and more than three-quarters of the patients rated their health status as good, very good, or excellent. Nevertheless, some areas of concern for patients were identified. Patients were worried about the guilt that they experience if they do not adhere to the dietary protein restriction and they were most concerned about high Phe levels during pregnancy. Further, tiredness was the most affected symptom, and the supplements' taste was considered a main issue for individuals with PKU. The overall impact of PKU on HRQoL was higher in women ($U = 1315.5, p = .012$) and in adults with a lower IQ ($r_s = -0.448, p = .005$). The overall impact of dietary protein restriction was higher in adults with higher concurrent Phe levels ($r_s = 0.272, p = .007$) and higher Phe levels during the past year ($r_s = 0.280, p = .009$).

Conclusion The impact of PKU on most domains assessed in the PKU-QoL was considered to be low. These results likely reflect the successful implementation of the newborn screening resulting in the prevention of severe adverse long-term outcomes. However, a particular clinical focus should be given to patients with lower IQ, higher Phe levels, and women, as these variables were associated with a lower HRQoL.

[†]Roman Trepp and Regula Everts shared co-last authorship.

*Correspondence:
Regula Everts
regula.everts@insel.ch

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords Phenylketonuria, Health-related quality of life, Inherited metabolic disease, Cognition, Metabolic control

Background

Phenylketonuria (PKU, OMIM 261600) is a rare inborn error of metabolism affecting the catabolism of phenylalanine (Phe) to tyrosine. Mutations in the phenylalanine hydroxylase (*PAH*) gene lead to impaired activity of the *PAH* enzyme, which results in elevated levels of Phe in the blood and brain [1]. An early-initiated treatment consisting of a Phe-restricted diet and amino acid supplementation successfully prevents severe long-term sequelae, including mental retardation, neurological impairment, or psychiatric difficulties [2]. Pharmacological treatments, such as sapropterin dihydrochloride (BH₄, Kuvan®) or pegvaliase (Palynziq®), have been introduced, allowing patients a higher Phe intake [3]. However, a substantial amount of patients with classical PKU do not respond to sapropterin or display significant hypersensitivity reactions to the treatment with pegvaliase [3–5], leaving a Phe-restricted diet combined with an amino acid supplementation the treatment of choice for most patients with classical PKU.

Maintenance of a lifelong Phe-restricted diet is complex and adherence to treatment can be challenging for patients [6, 7]. In most adults with PKU, difficulties following dietary recommendations result in higher Phe levels than recommended according to the current guidelines [7, 8]. Issues with cognitive performance, depression, and irritability might concern adults with PKU and likely interfere with their daily lives [7]. Higher scores in depression, anxiety, or stress have been described in adults with early-treated classical PKU, and eating disorders are more prevalent than in the general population [9–11]. These PKU-related symptoms can affect health-related quality of life (HRQoL) of adults with early-treated PKU [12]. HRQoL refers to the subjective evaluation of health or illness and encompasses psychological, physical, and social domains of health [13, 14]. In addition to PKU-related symptoms affecting HRQoL, following a diet with a stringent restriction of natural protein can be stressful for patients and consequently also affects HRQoL [12]. Thus, a differentiation between PKU-related symptoms and dietary management requirements affecting HRQoL is important when investigating HRQoL in PKU [12].

Several studies suggest that health-related QoL in adults with early-treated PKU is comparable to healthy controls [15–18]. In contrast, Huijbregts et al. (2018) showed that adults with early-treated PKU display alterations in HRQoL, particularly concerning cognition, anger, and depressive moods [19]. One of the reasons for these inconsistent findings can be explained by the different assessments to evaluate HRQoL [18]. Several studies

use generic questionnaires to assess HRQoL which are likely not sensitive enough to capture subtle difficulties associated with PKU and dietary management [12, 18, 20]. For this reason, a PKU-specific QoL questionnaire has been developed, addressing four modules: symptoms associated with PKU, the impact of PKU, the impact of the dietary protein restriction on the patients' everyday life, and the administration of the amino acid supplementation [21]. Studies using the PKU-QoL questionnaire suggest that most domains indicate little or no impact of PKU and its treatment on HRQoL, reflecting the good overall health status of adults with PKU [21]. However, some difficulties remain and patients report issues concerning the emotional impact of PKU and feelings of guilt if dietary restrictions are not followed, the taste of the supplements, the anxiety of high Phe levels during pregnancy, or tiredness [1, 18, 21, 22].

Previous studies investigating HRQoL using the PKU-QoL often included small and mixed samples of patients with hyperphenylalaninemia, mild, moderate, and classical PKU, samples of early-treated and non-early treated patients (treated before vs. after 30 days of age), as well as patients treated with sapropterin or pegvaliase [18, 22–25]. Adults with mild PKU treated with sapropterin displayed a higher HRQoL than adults with classical PKU treated with a Phe-restricted diet [25]. More specifically, patients with classical PKU reported a greater impact of the amino acid supplementation compared to patients with mild or moderate PKU [18]. Also, the overall impact of dietary protein restriction and the impact of the amino acid supplementation was higher for patients not treated with sapropterin than those treated with sapropterin [18]. These results reflect the increased dietary constraints for adults with classical PKU and highlights the importance of focusing on adults with early-treated classical PKU treated with dietary restriction and amino acid supplementation [18].

To date, factors associated with HRQoL in adults with early-treated PKU have been insufficiently studied. Male patients, patients with lower education and patients with higher concurrent Phe levels displayed lower HRQoL [19, 23, 25, 26]. However, previous findings should be interpreted with caution due to the inclusion of heterogeneous samples including patients with classical and non-classical PKU, pediatric and adult patients with PKU, and the use of divergent QoL assessments [19, 23, 25, 26]. In healthy adults, HRQoL has been shown to vary in respect to age, with increasing age negatively affecting HRQoL [27]. Also, higher intelligence quotients (IQ) and executive functions are linked to higher HRQoL in healthy adults [28, 29]. Whether age, IQ, and

executive functions are related to HRQoL in adults with early-treated classical PKU remains to be investigated. Identifying patient characteristics associated with lower HRQoL is essential to provide the best medical care for this patient group.

The aim of this study was to investigate HRQoL in a large European sample of adults with early-treated classical PKU not treated with sapropterin or pegvaliase. We further aimed to explore associations between HRQoL and demographic, metabolic, and cognitive characteristics to extend our understanding of HRQoL in adults with early-treated classical PKU and to identify patients at risk for reduced HRQoL.

Methods

Study design and participants

This cross-sectional study includes data from five research projects that were carried out in Hungary, Italy, Spain, Switzerland [30], and Turkey. A subset of the data has previously been published [23, 24, 31]. In detail, data was prospectively collected between 2016 and 2022 at the Department of Internal Medicine and Oncology of the Semmelweis University in Budapest (Hungary), the Division of Inherited Metabolic Diseases of the University Hospital in Padova (Italy), the Unit of Diagnosis and Treatment of Congenital Metabolic Diseases of the University Clinical Hospital in Santiago de Compostela (Spain), the Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism of the University Hospital in Bern (Switzerland), and the Department of Nutrition and Dietetics of the Ankara University in Ankara (Turkey). Patients were recruited via their treating specialist or patient organizations. Details about the recruitment process have been previously described [23, 24, 30, 31]. The studies were approved by the local ethic committees of Hungary, Italy, Spain, Switzerland, and Turkey and were performed in accordance with the Declaration of Helsinki. All participants gave written informed consent before participation.

Participants included in this study were aged ≥ 18 years, diagnosed with early-treated classical PKU after a positive newborn-screening, and treated with a Phe-restricted diet and amino acid supplements according to the current guidelines [32]. Exclusion criteria were a treatment with sapropterin dihydrochloride (BH4, Kuvan®) or pegvaliase (Palynziq®). 173 participants were identified from the five research projects. In total, 49 patients were ineligible and therefore not included in the present study. 28 patients did not have classical PKU, 12 patients were not early-treated, and nine patients were treated with either sapropterin or pegvaliase. The final sample consisted of 124 adults with early-treated classical PKU.

Outcomes

Health-related quality of life

The PKU-QoL is a disease-specific questionnaire designed to evaluate the impact of PKU and its treatment on HRQoL [21]. In contrast to more generic assessments of HRQoL, such as the EQ-5D [33], SF-12 [34], or SF-36 [35], the PKU-QoL is sensitive in terms of detecting specific difficulties related to PKU [18]. All participants completed the adult version of the PKU-QoL. This questionnaire consists of 65 items and allows the calculation of 35 domain scores across four modules (symptoms, PKU in general, supplement administration, and dietary protein restriction). Domain scores range from 1 to 100 whereby scores ≤ 25 reflect little or no impact, domain scores between 26 and 50 suggest moderate impact, domain scores between 51 and 75 indicate major impact, and domain scores > 75 reflect severe impact [18]. The PKU-QoL was scored using the PKU-QoL electronic scorer (PKU-QoL © Biomarin Pharmaceutical Inc.).

We defined two variables of particular interest in this study: “overall impact of PKU” and “overall impact of dietary protein restriction”. In contrast to most of the single-item domain scores of the PKU-QoL, these are two multi-item domain scores and include 13 items each. The domain score “overall impact of PKU” reflects the emotional, practical, and social impact of PKU (item example: “PKU negatively impacts my relationship with my partner”). The domain score “overall impact of dietary protein restriction” reflects the practical and social implications of dietary protein restriction (item example: “In the past 7 days, I felt different because I couldn’t eat or drink what others ate”). Items are scored on a 5- or 6-point Likert scale [21]. As the impact of PKU on HRQoL can be determined by cultural factors, a cross-cultural adaptation was performed for seven countries (Germany, France, Italy, Spain, the Netherlands, Turkey, and UK) during the development of the PKU-QoL [21].

Demographic, metabolic, cognitive, and psychosocial data

Demographic data (age and sex) were collected at the study visit. Information about Phe levels was available for the Hungarian, Italian, Spanish, and Swiss sample. Concurrent Phe levels were obtained from either blood plasma or dried blood spots. We additionally calculated the mean Phe levels of the past year (except for the Spanish sample, where we had information about the past two years). Plasma Phe was measured using high-performance ion-exchange liquid chromatography, and Phe levels in dried blood spots were assessed with tandem mass spectrometry in the laboratories of the study centers in the respective country. A calibration factor was not applied to adjust for discrepancies between Phe levels obtained from blood plasma or dried blood spots due to large variability between analytical methods [36]. IQ was

integrated as a broad cognitive measure describing the patients’ general cognitive state. Furthermore, we chose to focus on IQ as this was the only cognitive outcome available in several samples (Swiss and Spanish sample). In the Swiss sample, IQ was assessed using a short form of the Wechsler Adult Intelligence Scale (WAIS-IV; [37, 38]) at the time of the HRQoL assessment. In the Spanish sample, IQ was assessed using the Kaufmann Brief Intelligence Test (KBIT; [39]) or the Wechsler Intelligence Test for Children (WISC-IV; [40]) as part of the clinical routine and was performed before the HRQoL assessment (age at the time of IQ assessment 13.82 years ± 2.14).

For a subgroup (Swiss sample, *n*=30), information about performance in executive function and depressive symptoms was available. Executive functions were assessed using the theoretical framework of Miyake et al. (2000) [41]. In detail, working memory was measured using the subtest letter-number sequencing of the WAIS-IV, inhibition was evaluated using the third condition of the Color-Word Interference Test (CWIT) of the Delis-Kaplan Executive Function Test (D-KEFS; [42]), and cognitive flexibility was assessed using the fourth condition of the CWIT. According to the manuals, raw scores were transformed into age-corrected scaled scores (mean: 10 ± 3). We calculated the mean score of the three executive function domains to obtain a composite score of executive functions [43]. The Beck-Depression Inventory (BDI-II; [44]) was administered to assess depressive symptoms. This self-administered questionnaire consists of 21 items evaluating the level of depression with a score ranging from 0 to 63.

Statistical analysis

To reduce the number of variables for the statistical analyses, we chose two out of the 35 domain scores of the PKU-QoL that were of particular interest, namely the multi-item domains “overall impact of PKU” and “overall impact of dietary protein restriction”. We did not compare the five European samples with respect to demographic, metabolic, and cognitive characteristics or HRQoL, given that the sample size sample varied considerably. Non-parametric statistics were used as not all variables were normally distributed. Categorical variables

are displayed in frequencies and percentages, and continuous variables in medians and interquartile ranges (IQR). Associations between demographic, metabolic, cognitive variables, and the PKU-QoL were examined with two-sided Spearman correlations or Mann-Whitney *U*-tests. To further investigate the relationship between demographic, metabolic, and cognitive variables, a multiple linear regression was conducted to examine the variance of the dependent variable (“overall impact of PKU” and “overall impact of dietary protein restriction”, respectively) that is explained by the independent variables (age, sex, concurrent Phe levels, and IQ). Concurrent Phe levels and not Phe levels of the past year were chosen as an independent variable because more data was available for concurrent Phe levels.

Effect sizes *r* were calculated for Spearman correlations and Mann-Whitney *U*-tests and Cohens *f*² were computed for multiple regressions. Effect sizes are interpreted according to Cohen [45] with small effect for *r* = .1 and *f*² = 0.02, medium effect for *r* = .3 and *f*² = 0.15, and large effect for *r* = .5 and *f*² = 0.35. Further, 95% confidence intervals (CI) are reported for effect sizes to estimate the size of the effect rather than emphasizing statistical significance [46, 47]. To account for multiple testing, the false discovery rate (FDR) correction was applied [48]. Statistical analysis was performed with SPSS, version 28. Data visualization was conducted using the R package ggplot2 [49].

Results

Demographic, metabolic, and cognitive data are presented in Table 1. Concurrent Phe levels were available for 108 participants (87.1%), and Phe levels from the past year before study participation were available for 95 participants (76.6%). 71 participants (65.7%) had higher concurrent Phe concentrations than suggested by the current European guidelines, which recommend maintaining a Phe level below 600 μmol/l [32]. Regarding the Phe levels during the year before study participation, 54 participants (56.8%) had a mean Phe level higher than 600 μmol/l. IQ was available for 37 participants (29.8%) from Spain and Switzerland, and the median IQ was 97.0 and hence within the normative range.

Table 1 Demographic, metabolic, and cognitive data

	Total <i>n</i> = 124	Hungary <i>n</i> = 66	Italy <i>n</i> = 5	Spain <i>n</i> = 7	Switzerland <i>n</i> = 30	Turkey <i>n</i> = 16
Age, years	30.0 (22.5–37.6)	32.5 (24.6–40.1)	30.0 (22.0–34.5)	30.6 (20.7–37.4)	35.5 (25.0–38.2)	22.0 (20.3–23.0)
Sex, male	59 (47.6%)	35 (53.0%)	2 (40.0%)	2 (28.6%)	17 (56.7%)	3 (18.8%)
Concurrent Phe, μmol/l	703.7 (540.0–907.8)	643.0 (503.8–835.0)	1073.0 (738.4–1411.0)	705.2 (614.4–1107.8)	741.0 (583.5–959.0)	-
Phe past year, μmol/l	650.0 (507.7–854.8)	598.3 (485.6–798.2)	1004.0 (677.7–1252.0)	696.2 (641.7–783.9)	813.3 (576.6–1053.7)	-
IQ	97.0 (90.0–106.0)	-	-	95.0 (81.0–101.0)	97.0 (90.0–107.5)	-

Notes. Data are presented in frequencies (%) for categorical variables and in median (IQR) for continuous variables. Concurrent Phe available for *n*=108, Phe past year for *n*=95, and IQ for *n*=37

Health-related quality of life

Table 2 shows the 35 domain scores of the PKU-QoL. 27 of the 35 domain scores (77.1%) showed no or little impact of PKU (scores between 0 and 25). The four most affected domains were “tiredness”, “anxiety - Phe levels during pregnancy”, “taste - supplements”, and “guilt if dietary protein restriction not followed”. Except for the domain “anxiety - Phe levels during pregnancy,” which was estimated to be a major impact, the other three dimensions were reported as moderate. For the domain “self-rated health status”, a median score of 50 suggests a moderate impact. This is misleading insofar as a score of 50 in this domain indicates that patients rated their overall health status as good. We therefore prefer to report

the following: 1.7% of patients rated their overall health status as poor, 20.7% as fair, 28.9% as good, 28.1% as very good, and 20.7% as excellent.

The median scores of “overall impact of PKU” and “overall impact of dietary protein restriction” were 21 and 17, respectively, which suggest no or little impact (bold domains in Table 2). Detailed information about the distribution of the data is displayed in Fig. 1. Although the median scores were both interpreted as no or little impact, a considerable part of the patients reported a moderate or major impact of PKU or dietary protein restriction, respectively. These two domain scores were considered for further statistical analyses.

Table 2 Health-related quality of life

Module	Domain	Total n = 124	Hungary n = 66	Italy n = 5	Spain n = 7	Switzerland n = 30	Turkey n = 16	
Symptoms	Self-rated health status	50 (25–50) ³	50 (25–75) ³	50 (25–63)	50 (25–75)	25 (0–50)	50 (25–50)	
	Headaches	25 (0–50) ²	25 (0–50) ²	25 (13–50)	25 (0–50)	25 (0–50)	25 (0–50)	
	Stomach Aches	0 (0–25) ³	0 (0–25) ³	25 (0–50)	0 (0–50)	0 (0–25)	25 (0–25)	
	<i>Tiredness</i>	50 (25–50) ²	50 (25–50) ²	50 (13–75)	50 (50–75)	25 (0–50)	38 (7–69)	
	Lack of concentration	25 (0–50) ³	25 (0–50) ³	50 (13–75)	50 (25–50)	25 (0–50)	25 (0–44)	
	Slow thinking	0 (0–25) ²	0 (0–44) ²	25 (0–63)	25 (0–50)	0 (0–25)	13 (0–25)	
	Trembling hands	0 (0–25)	0 (0–25)	0 (0–50)	0 (0–25)	0 (0–0)	0 (0–25)	
	Irritability	25 (0–50) ²	25 (0–50) ²	25 (13–63)	25 (25–50)	25 (0–50)	25 (6–25)	
	Aggressiveness	0 (0–25) ¹	0 (0–25) ¹	0 (0–50)	25 (0–50)	0 (0–0)	0 (0–19)	
	Moodiness	25 (0–50)	25 (0–50)	25 (25–75)	50 (50–100)	13 (0–31)	38 (25–50)	
	Sadness	0 (0–50) ¹	0 (0–50) ¹	25 (13–50)	25 (25–50)	0 (0–6)	38 (25–50)	
	Anxiety	0 (0–50) ¹	25 (0–50) ¹	25 (0–63)	50 (50–75)	0 (0–0)	25 (0–50)	
	PKU in general	Emotional impact of PKU	35 (20–50) ³	35 (20–50) ³	40 (35–63)	50 (45–60)	20 (15–30)	40 (35–60)
		Practical impact of PKU	13 (0–25) ¹⁸	13 (0–25) ⁵	19 (4–29)	31 (25–31)	8 (6–18)	- ¹³
Social impact of PKU		11 (0–19) ²	7 (0–19) ²	19 (15–25)	25 (19–31)	6 (0–13)	17 (8–25)	
Overall impact of PKU		21 (12–31)⁴	21 (13–30)⁴	25 (23–42)	37 (33–42)	13 (10–17)	35 (20–44)	
Anxiety - Blood test		0 (0–0) ⁷	0 (0–13) ⁷	0 (0–13)	0 (0–50)	0 (0–0)	0 (0–10)	
Anxiety - Phe levels		25 (25–75) ¹	25 (0–63) ¹	50 (50–63)	75 (75–100)	25 (25–31)	50 (25–75)	
<i>Anxiety - Phe levels during pregnancy</i>		75 (25–100)	50 (25–100)	75 (50 - NA)	100 (75–100)	75 (25–88)	75 (25–100)	
Financial impact of PKU		25 (0–50) ¹	0 (0–25) ¹	0 (0–13)	75 (50–100)	25 (0–31)	25 (0–50)	
Information on PKU		25 (0–50) ³	25 (0–50) ³	50 (13–50)	50 (25–50)	25 (0–25)	25 (0–44)	
Supplement administration		Adherence to supplements	8 (2–33) ²⁸	8 (0–31) ¹⁴	50 (33–63)	8 (0–25)	8 (4–25) ¹	- ¹³
	Guilt if poor adherence to supplements	25 (25–75) ⁶	38 (25–75) ⁶	50 (25–50)	25 (0–25)	25 (25–50)	25 (25–50)	
	Impact of supplements on family	0 (0–0) ⁵	0 (0–0) ⁵	0 (0–50)	0 (0–0)	0 (0–0)	0 (0–25)	
	Practical impact of supplements	6 (0–25) ⁷	0 (0–13) ⁷	25 (13–31)	38 (31–44)	6 (0–13)	38 (19–69)	
	<i>Taste - Supplements</i>	50 (25–50) ⁸	50 (25–50) ⁸	50 (50–63)	50 (25–50)	25 (25–50)	50 (6–50)	
	Dietary protein restriction	Food temptation	32 (0–50) ⁶	25 (0–50) ⁵	63 (44–75)	50 (25–50)	25 (13–50) ¹	19 (0–50)
Adherence to dietary protein restriction		19 (6–30) ¹⁷	19 (10–34) ¹⁰	35 (28–58)	25 (13–25)	13 (5–25) ¹	25 (6–33) ⁶	
Practical impact of dietary protein restriction		29 (15–39) ⁹	25 (11–36) ⁸	39 (27–54)	39 (25–50)	21 (11–34) ¹	54 (39–75)	
Social impact of dietary protein restriction		4 (0–13) ⁶	5 (0–13) ⁶	25 (15–38)	4 (0–33)	0 (0–4)	13 (5–29)	
Overall impact of dietary protein restriction		17 (10–29)⁹	17 (9–25)⁸	29 (23–46)	27 (13–52)	13 (7–18)¹	35 (29–46)	
Overall difficulty following dietary protein restriction		25 (0–50) ⁷	25 (0–50) ⁷	50 (25–75)	0 (0–50)	25 (0–25)	50 (0–50)	
<i>Guilt if dietary protein restriction not followed</i>		50 (25–75) ⁶	50 (25–75) ⁶	50 (25–63)	75 (50–75)	25 (25–56)	75 (38–94)	
Taste - Low-protein food		25 (25–50) ⁹	25 (25–50) ⁶	50 (50–50) ¹	25 (25–25)	25 (0–25) ²	25 (0–50)	
Food enjoyment	0 (0–25) ⁸	0 (0–25) ⁶	75 (50–75)	0 (0–25)	0 (0–0)	25 (25–88)		

Notes. All values were rounded to the nearest integer. Number of missing data is indicated in superscripted numbers. Four most affected domains are presented in *italic*. The two domains of interest in this study are presented in bold. Domain scores are interpreted as follows: ≤ 25=little or no impact; 26–50=moderate impact; 51–75=moderate to major impact; > 75=severe impact (18). NA=Not available due to the limited number of female participants, n=3

Associations between health-related quality of life and demographic, metabolic, and cognitive characteristics

The overall impact of PKU was not significantly associated with age ($r_s = -0.125, p = .173, 95\% \text{ CI } [-0.30, 0.06]$). Women (median=24, IQR=16–35) rated the overall impact of PKU significantly higher compared to men (median=17, IQR=10–29; $U = 1315.5, p = .012, r = .23, 95\% \text{ CI } [0.05, 0.39]$; see also Fig. 2, top left). This comparison survived FDR correction ($p_{FDR} = 0.032$). Concurrent Phe levels ($r_s = 0.196, p = .046, 95\% \text{ CI } [0.00, 0.38]$) but not Phe levels of the past year ($r_s = 0.167, p = .114, 95\% \text{ CI } [-0.04, 0.36]$), were significantly associated with the overall impact of PKU, which, however, did not persist after FDR correction ($p_{FDR} = 0.092$). A significant negative association with medium effect sizes was found for overall impact of PKU and IQ ($r_s = -0.448, p = .005, 95\% \text{ CI } [-0.68, -0.13]$), with higher overall impact of PKU relating to lower IQ (Fig. 2, top right). This association survived FDR correction ($p_{FDR} = 0.027$).

A multiple linear regression with age, sex, concurrent Phe, and IQ as independent variables and overall impact of PKU as dependent variable showed that 18.6% of the variance in the overall impact of PKU could be explained by the independent variables ($F [4,32] = 3.051, p = .031, f^2 = 0.23, 95\% \text{ CI } [-0.01, 0.62]$). IQ was a significant predictor ($p = .005$) whereas age ($p = .891$), sex ($p = .531$), and concurrent Phe ($p = .306$) were not. After FDR correction, the regression model was not significant ($p_{FDR} = 0.071$).

The overall impact of dietary protein restriction was neither significantly correlated with age ($r_s = -0.111, p = .237, 95\% \text{ CI } [-0.29, 0.07]$) nor IQ ($r_s = -0.076, p = .658, 95\% \text{ CI } [-0.40, 0.26]$). There was no sex difference

(men median=17, IQR=10–26; women median=19, IQR=11–33) regarding the overall impact of dietary protein restriction ($U = 1509.0, p = .439, r = .07, 95\% \text{ CI } [-0.11, 0.25]$). Concurrent Phe levels ($r_s = 0.272, p = .007, 95\% \text{ CI } [0.08, 0.45]$) and Phe levels of the past year ($r_s = 0.280, p = .009, 95\% \text{ CI } [0.07, 0.47]$) were significantly associated with the overall impact of dietary protein restriction, with higher Phe levels relating to higher overall impact of dietary protein restriction (Fig. 2, bottom row). Significant results survived FDR correction ($p_{FDR} = 0.028$ and $p_{FDR} = 0.029$) with small effect sizes. The multiple regression model with overall impact of dietary protein restriction as dependent variable was not significant ($F [4,31] = 0.442, p = .777, f^2 = 0.00$).

Subgroup analyses

Significant results of the subgroup analyses in the Swiss sample are displayed in Fig. 3. The median (IQR) composite score for executive functions was 9.7 (8.3–11). There was a significant negative association between the overall impact of PKU and executive functions ($r_s = -0.526, p = .003, 95\% \text{ CI } [-0.76, -0.18]$) with a large effect size, indicating that patients with a high overall impact of PKU displayed worse executive functions. The median (IQR) depression score was 1 (0–5.5). A significant positive correlation with a large effect size was found between the overall impact of PKU and the depression score ($r_s = 0.615, p < .000, 95\% \text{ CI } [0.30, 0.81]$), with a high overall impact of PKU relating to a higher depression score. Findings of the subgroup analyses remained significant after FDR-correction ($p_{FDR} = 0.024$ and $p_{FDR} < 0.000$). The overall impact of dietary protein restriction was neither




Fig. 1 Distribution of the two domain scores overall impact of PKU and overall impact of dietary protein restriction. The vertical black line is the median. The percentages reflect the proportion of participants in the corresponding category




Fig. 2 Significant associations between overall impact of PKU / overall impact of dietary protein restriction and demographic, metabolic, and cognitive characteristics (surviving FDR correction). The blue line represents the correlation coefficient with 95% CI in grey. A boxplot is presented for the categorical variable sex. p =significance value, r_s = Spearman’s correlation coefficient, U =Mann-Whitney U

significantly related to executive functions ($r_s = 0.079$, $p=.685$, 95% CI [-0.30, 0.43]) nor to the depression score ($r_s = 0.327$, $p=.083$, 95% CI [-0.06, 0.63]).

Discussion

In this cross-sectional European study including 124 adults with early-treated classical PKU, we showed that the majority of the domains assessed with the PKU-QoL indicated no or little impact of PKU on HRQoL. More than three-quarters of the patients rated their

health status as good, very good, or excellent. However, participants were worried about high Phe levels during pregnancy and were concerned about the guilt if dietary protein restriction was not followed. Tiredness was the most affected symptom and the supplements’ taste was considered a main issue for individuals with PKU. The medians of overall impact of PKU and overall impact of dietary protein restriction were considered to be low. Nevertheless, the overall impact of PKU was higher in females and participants with a lower IQ. The overall




Fig. 3 Associations between the overall impact of PKU and executive functions and the depression score in the Swiss subsample ($n=30$). The blue line represents the correlation coefficient with 95% CI in grey. Results remained the same when the outlier (BDI-II score of 24) was excluded. p =significance value, r_s = Spearman's correlation coefficient

impact of protein restriction was higher in patients with higher concurrent Phe levels and higher Phe levels during the past year.

77.1% of the domain scores assessed in the PKU-QoL questionnaire showed no or little impact of PKU on HRQoL and a majority of the participants rated their health status as good, very good, or excellent. This is consistent with previous studies [15, 16, 23] and likely reflects the successful implementation of the newborn screening resulting in the prevention of severe adverse long-term outcomes. Similar to other chronic or serious diseases, where patients often report a good HRQoL, adults with early-treated classical PKU likely undergo positive adaptation processes and thus show good HRQoL [12, 50]. Of note, it is important to consider that most participants were recruited via their treating specialist at their metabolic clinic or via patient organizations, which could bias our sample. Some adults with PKU are lost to follow-up by metabolic clinics and are probably not adhering to a life-long diet [51, 52]. This circumstance is also reflected in a large survey including adults with PKU recruited via websites and social media, which suggested that social isolation and stigmatization associated with dietary management represent a burden for patients [7]. Thus, the results of the present study likely refer to patients who are followed up by a metabolic clinic and may not be applicable to all patients.

Despite the overall good outcome in terms of HRQoL in adults with early-treated PKU, some areas of concern have been identified in the present study. Future research should particularly focus on the taste of the amino acid

supplements, as this was a significant issue for patients, which can negatively impact compliance to the supplementation [53]. The taste of the ready-to-use amino acid supplements is continuously being improved, however, to date full reimbursement of these confectioned products by health insurance is not guaranteed in some countries [54]. Also, patients were concerned about the guilt that they experience if they do not adhere to the dietary protein restriction. Dietary management is often perceived as stressful and represents a burden for patients, which likely leads to difficulties associated with the adherence to the current dietary recommendations [55–57]. In fact, PKU-related symptoms but also dietary management itself can negatively affect HRQoL [12]. There is still no international consensus on ideal Phe concentrations during adulthood [56]. The current European guidelines suggest maintaining a Phe level below 600 $\mu\text{mol/l}$ [32], but this has been criticized due to limited evidence for safe target Phe concentrations and the difficulties for patients to reach these treatment goals [56, 58]. Our data show that patients feel guilty if they do not follow their diet. This further points to the idea that overtreatment might negatively impact their psychological well-being with no or limited potential benefits [56]. It is therefore of crucial importance to investigate in a randomized controlled trial whether high Phe levels affect HRQoL, cognitive, and cerebral parameters in adults with early-treated PKU to increase our understanding of safe target Phe levels for adults with early-treated classical PKU [30].

Investigating patient characteristics associated with HRQoL is essential to identify patients at risk for lower

HRQoL and consequently provide the best medical care. Regarding the overall impact of PKU, our data show that women displayed a higher overall impact of PKU than men. This is in contrast to a study with 17 adults with PKU, suggesting worse HRQoL in men compared to women [25]. These conflicting results can be explained by the small and heterogeneous sample in the previous study, as they included patients with mild and classical PKU and patients treated with sapropterin. The sex difference regarding the overall impact of PKU found in the present study is, however, in line with studies in other clinical populations suggesting that women generally report worse HRQoL than men [59–63]. Women differ from men in their health perception and behavior and how they report symptoms [64–66], all of which can influence the self-reported HRQoL. Also, the fear of maternal PKU and its teratogenic effects during prenatal development could also contribute to a higher impact of PKU on HRQoL in women compared to men [67]. Further, differences in socioeconomic status (SES) might contribute to the sex difference observed in the present study [68]. Women tend to have lower incomes than men; thus, sex disparities in HRQoL can also partly be attributed to the lower SES of women [68]. We were unable to include SES in the present study and examine its association with HRQoL because of difficulties in comparing income and educational levels across countries. To overcome this, future studies should implement a standardized assessment to evaluate SES, such as the Hollingshead index [69].

Our findings further suggest that the overall impact of PKU is lower in participants with a higher IQ. Given the non-directional relationship of this association, it can be argued that a higher IQ is a protective factor that might protect against the negative impact of PKU [70]. At the same time, PKU adversely affects IQ, and lower IQ has been observed in adults with poorer metabolic control [71, 72]. Further, we found a positive association between the overall impact of dietary protein restriction and concurrent Phe levels as well as Phe levels of the past year. Maintaining a strict diet in classical PKU can be a demanding and sometimes frustrating task. Particularly in adulthood, with growing personal independence and after years of strict diet, these results could reflect the patients' resentment towards a strict diet and maintaining low Phe levels. Although the impact of PKU on HRQoL was considered to be low in the majority of the domains assessed in this study, specific patient characteristics are associated with lower HRQoL in adults with early-treated classical PKU. A particular focus should be given to patients with lower IQ, higher Phe levels, and women, as they are at risk for lower HRQoL.

We further examined in the Swiss subsample whether executive functions and depressive symptoms were

related to the overall impact of PKU and the overall impact of dietary protein restriction. Executive functions and depressive symptoms were strongly associated with the overall impact of PKU but unrelated to the overall impact of dietary protein restriction. These results suggest that the overall impact of PKU is higher in patients with worse executive functions and higher depression scores. This is in line with studies including other clinical populations, suggesting that executive functions and depressive symptoms are associated with HRQoL [73–77]. The findings of the present study highlight the importance of focusing on cognitive and psychosocial factors in the treatment of PKU, enabling the identification of patients that are particularly vulnerable to impaired HRQoL.

A strength of the present study is the size and homogeneity of the European sample including 124 adults with early-treated classical PKU, a group of patients neither treated with sapropterin nor with pegvaliase. Further, our results show medium to large effect sizes that withstand correction for multiple testing. The study also has some limitations. First, we did not statistically compare the different national subsamples regarding their HRQoL as the sample sizes varied considerably across countries. Also, the included countries differ in their cultural backgrounds and health care systems – both aspects can influence HRQoL. However, the PKU-QoL questionnaire has been cross-culturally adapted for Germany, Italy, Spain, and Turkey to minimize the impact of these influences on HRQoL [21]. Of note, no cross-cultural adaptation of the questionnaire has been performed for Hungary (for more details see [23]). Second, IQ was assessed with two different measures. However, the literature suggests that IQ scores that are assessed with different measures are highly correlated [78], hence we start from the premise that comparability between IQ measures is given. Furthermore, IQ was only available in a subsample of 37 participants. In addition, in the Spanish sample ($n=7$) IQ was assessed during childhood and thus, years before the HRQoL assessment. Previous studies on patients with PKU have shown stable cognitive functions across childhood and adulthood [79]. To find out whether the different age at IQ assessment influenced the association between IQ and HRQoL, analyses were re-performed with only the patients from the Swiss subgroup ($n=30$). The results remained the same, showing a significant association between IQ and overall impact of PKU. To conclude, the association between IQ and HRQoL should be interpreted in light of this limitation. Further, IQ is a general measure not sensitive enough to detect minor cognitive alterations, especially in adult patients. Third, comparability of the disease-specific HRQoL questionnaire to other HRQoL instruments or to HRQoL in the healthy population is limited as the PKU-QoL

questionnaire is a PKU-specific instrument. At the same time, the specificity of the PKU-QoL questionnaire is a strength of this study in identifying areas of concern for patients with a particular focus on dietary aspects. The PKU-QoL questionnaire could ideally be complemented with the newly developed PKU Symptom Severity and Impacts Scale (PKU-SSIS) addressing neuropsychological and physical symptoms of PKU and its impact on HRQoL [80]. Fourth, additional variables that might be associated with HRQoL, for instance, the SES, were not included in the present study because of difficulties in comparing income and educational levels across countries.

Conclusion

The present study shows that for more than three-quarters of the domains assessed in the PKU-QoL, the impact of early-treated classical PKU on HRQoL was considered to be low. These results reflect the successful implementation of the newborn screening preventing severe adverse long-term outcomes. However, our results reveal that a particular focus should be given to adults with a lower IQ, higher Phe levels, and women, as these characteristics were associated with a higher overall impact of PKU and dietary protein restriction, respectively. These findings further contribute to a better understanding of the complex nature of demographic, metabolic, and cognitive factors associated with HRQoL and show the importance of including patient-reported outcome measures to identify areas of particular concern for patients with classical PKU.

List of abbreviations

BDI-II	Beck Depression Inventory
BH4	Sapropterin dihydrochloride
CWIT	Color-Word Interference Test
CI	Confidence interval
D-KEFS	Delis-Kaplan Executive Function Test
EQ-5D	European Quality of Life 5 Dimensions
FDR	False discovery rate
HRQoL	Health-related quality of life
IQ	Intelligence quotient
IQR	Interquartile range
K-BIT	Kaufmann Brief Intelligence Test
PAH	Phenylalanine hydroxylase
Phe	Phenylalanine
PKU	Phenylketonuria
PKU-QoL	Phenylketonuria quality of life questionnaire
SES	Socioeconomic status
SF-12	Short Form 12
SF-36	Short Form 36
WAIS-IV	Wechsler Adult Intelligence Scale
WISC-IV	Wechsler Intelligence Test for Children

Acknowledgements

We want to thank all participants that participated in the present study.

Authors' contribution

SMA was involved in the conceptualization of the study, the data acquisition, the data analysis, and wrote the manuscript. RM and RT contributed to the conceptualization and funding of the study, the data acquisition, and edited the manuscript. MH, PR, AGB, IMA, AHA, APB, ABB, CC, and JC helped with the data acquisition and edited the manuscript. RE was involved in the

conceptualization and funding of the study and the data acquisition, edited the manuscript, and provided supervision. All authors read and approved the final manuscript.

Funding

This study was supported by the Swiss National Science Foundation (project grant 192706 and 184453), the Bangerter Rhyner Foundation (Switzerland), the Vontobel Foundation (Switzerland), a young investigator grant from the Inselspital Bern (CTU grant, Switzerland), the Nutricia Metabolics Research Fund (Netherlands), and the Fondation Rolf Gaillard pour la recherche en endocrinologie, diabétologie et métabolisme (Switzerland). The funders had no involvement in the study design, collection, analysis, and interpretation of the data.

Data Availability

The datasets used and analyzed during the current study are not publicly available in order to protect patient privacy. However, the datasets are available from the corresponding author (regula.everts@insel.ch) upon reasonable request.

Declarations

Ethics approval and consent to participate

The studies were approved by the local ethic committees of Hungary, Italy, Spain, Switzerland, and Turkey and were performed in accordance with the Declaration of Helsinki. All participants gave written informed consent before participation.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

²Support Center for Advanced Neuroimaging (SCAN), Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

³Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary

⁴Faculty of Health Sciences, Department of Nutrition and Dietetics, Ankara University, Ankara, Turkey

⁵Division of Internal Medicine, European Reference Network for Hereditary Metabolic Disorders (MetabERN), University Clinical Hospital, Santiago de Compostela, Spain

⁶Neurological Unit, St. Bassiano Hospital, Bassano del Grappa, Italy

⁷Division of Inborn Metabolic Diseases, Department of Pediatrics, University Hospital, Padua, Italy

⁸Division of Neuropediatrics, Development and Rehabilitation, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Received: 4 January 2023 / Accepted: 11 September 2023

Published online: 22 September 2023

References

1. van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM, Phenylketonuria. *Nat Rev Dis Primers*. 2021;7(1).
2. Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, et al. Management of phenylketonuria in Europe: Survey results from 19 countries. *Mol Genet Metab*. 2010;99(2):109–15.
3. Elsas LJ, Greto J, Wierenga A. The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria. *Mol Genet Metab*. 2011;102(4):407–12.
4. Fiege B, Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in Phenylketonuria. *J Pediatr*. 2007;150(6):627–30.

5. Hausmann O, Daha M, Longo N, Knol E, Müller I, Northrup H, et al. Pegvaliase: immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy. *Mol Genet Metab*. 2019;128(1–2):84–91.
6. Bhashyam SS, Marsh K, Quartel A, Weng HH, Gershman A, Longo N et al. A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: a study of patients' preferences. *Mol Genet Metab Rep*. 2019;21.
7. Ford S, O'Driscoll M, MacDonald A. Living with Phenylketonuria: Lessons from the PKU community. *Mol Genet Metab Rep*. 2018;17:57–63.
8. MacDonald A, Van Rijn M, Gokmen-Ozel H, Burgard P. The reality of dietary compliance in the management of phenylketonuria. *J Inher Metab Dis*. 2010;33(6):665–70.
9. Jahja R, Huijbregts SCJ, de Sonnevle LMJ, van der Meere JJ, Legemaat AM, Bosch AM, et al. Cognitive profile and mental health in adult phenylketonuria: a PKU-COBESO study. *Neuropsychology*. 2017;31(4):437–47.
10. Bilder DA, Kabori JA, Cohen-Pfeffer JL, Johnson EM, Jurecki ER, Grant ML. Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. *Mol Genet Metab*. 2017;121(1):1–8.
11. Clacy A, Sharman R, McGill J. Brief Report Depression, anxiety, and stress in young adults with Phenylketonuria: Associations with Biochemistry. *J Dev Behav Pediatr*. 2014;35(6):388–91.
12. Olofsson S, Grälén K, Hoxer C, Okhuoya P, Persson U. The impact on quality of life of diet restrictions and disease symptoms associated with phenylketonuria: a time trade-off and discrete choice experiment study. *Eur J Health Econ*. 2022;23(6):993–1005.
13. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. *N Engl J Med*. 1996;334(13):835–40.
14. Fontaine KR, Bartlett SJ. Estimating Health-Related quality of life in obese individuals. *Disease Manage Health Outcomes*. 1998;3(2):61–70.
15. Bosch AM, Tybout W, van Spronsen FJ, de Valk HW, Wijburg FA, Grootenhuys MA. The course of life and quality of life of early and continuously treated dutch patients with phenylketonuria. *J Inher Metab Dis*. 2007;30(1):29–34.
16. Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J, et al. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). *Health Qual Life Outcomes*. 2008;6:1–7.
17. Burlina AP, Lachmann RH, Manara R, Cazzorla C, Celato A, van Spronsen FJ, et al. The neurological and psychological phenotype of adult patients with early-treated phenylketonuria: a systematic review. *J Inher Metab Dis*. 2019;42(2):209–19.
18. Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, et al. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven european countries. *Orphanet J Rare Dis*. 2015;10(1):1–14.
19. Huijbregts SCJ, Bosch AM, Simons QA, Jahja R, Brouwers MCGJ, De Sonnevle LMJ, et al. The impact of metabolic control and tetrahydrobiopterin treatment on health related quality of life of patients with early-treated phenylketonuria: a PKU-COBESO study. *Mol Genet Metab*. 2018;125(1–2):96–103.
20. Demirdas S, Maurice-Stam H, Boelen CCA, Hofstede FC, Janssen MCH, Langendonk JG, et al. Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study. *Mol Genet Metab*. 2013;110:49–56.
21. Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, et al. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients' and parents' quality of life: the phenylketonuria - quality of life (PKU-QOL) questionnaires. *Orphanet J Rare Dis*. 2015;10:1–18.
22. Luna PM, López-Paz JF, García M, Amayra I, Martínez O, Pérez M et al. Cognitive Functioning in Adults with Phenylketonuria in a Cohort of Spanish Patients. *Behavioural Neurology*. 2023;2023.
23. Barta AG, Sumánszki C, Turgonyi Z, Kiss E, Simon E, Serfőző C et al. Health Related Quality of Life assessment among early-treated hungarian adult PKU patients using the PKU-QOL adult questionnaire. *Mol Genet Metab Rep*. 2020;23.
24. Alptekin IM, Koc N, Gunduz M, Cakiroglu FP. The impact of phenylketonuria on PKU patients' quality of life: using of the phenylketonuria-quality of life (PKU-QOL) questionnaires. *Clin Nutr ESPEN*. 2018;27:79–85.
25. Cazzorla C, Cegolon L, Burlina AP, Celato A, Massa P, Giordano L, et al. Quality of life (QoL) assessment in a cohort of patients with Phenylketonuria. *BMC Public Health*. 2014;14:1–9.
26. Bik-Multanowski M, Didycz B, Mozrzyms R, Nowacka M, Kaluzny L, Cichy W, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. *J Inher Metab Dis*. 2008;31:415–8.
27. Ribeiro O, Teixeira L, Araújo L, Rodríguez-Blázquez C, Calderón-Larrañaga A, Forjaz MJ. Anxiety, depression and quality of life in older adults: trajectories of influence across age. *Int J Environ Res Public Health*. 2020;17(23):1–10.
28. Davis JC, Marra CA, Najafzadeh M, Liu-Ambrose T. The independent contribution of executive functions to health related quality of life in older women. *BMC Geriatr*. 2010;10:1–8.
29. Bain GH, Lemmon H, Teunisse S, Starr JM, Fox HC, Deary IJ, et al. Quality of life in healthy old age: Relationships with childhood IQ, minor psychological symptoms and optimism. *Soc Psychiatry Psychiatr Epidemiol*. 2003;38(11):632–6.
30. Trepp R, Muri R, Abgottspon S, Bosanska L, Hochuli M, Slotboom J, et al. Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial. *Trials*. 2020;21:1–11.
31. Burlina AP, Cazzorla C, Massa P, Loro C, Gualardi D, Burlina AB. The impact of a slow-release large neutral amino acids supplement on treatment adherence in adult patients with phenylketonuria. *Nutrients*. 2020;12(7):1–12.
32. Van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. The complete european guidelines on phenylketonuria: diagnosis and treatment. *Orphanet J Rare Dis*. 2017;12(1):1–56.
33. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20(10):1727–36.
34. Ware JE, Kosinski M, Keller SD. A 12-Item short-form Health Survey: construction of Scales and preliminary tests of reliability and validity. *Med Care*. 1996;34(3):220–33.
35. Ware JE. SF-36 Health Survey Update. *Spine (Phila Pa 1976)*. 2000;25(24):3130–9.
36. Stroup BM, Held PK, Williams P, Clayton MK, Murali SG, Rice GM, et al. Clinical relevance of the discrepancy in phenylalanine concentrations analyzed using tandem mass spectrometry compared with ion-exchange chromatography in phenylketonuria. *Mol Genet Metab Rep*. 2016;6:21–6.
37. Petermann F. Wechsler Adult Intelligence Scale. 4th ed. Frankfurt, Germany: Pearson; 2012.
38. van Ool JS, Hurks PPM, Snoeijen-Schouwenaars FM, Tan IY, Schelhaas HJ, Klinkenberg S, et al. Accuracy of WISC-III and WAIS-IV short forms in patients with neurological disorders. *Dev Neurorehabil*. 2018;21(2):101–7.
39. Kaufmann AS, Kaufmann NL. Kaufmann brief intelligence test (K-BIT). Circle Pines, MN: American Guidance Service; 1990.
40. Petermann F, Petermann UJ. Wechsler Intelligence Scale for Children - Fourth Edition. Frankfurt, Germany: Pearson; 2012.
41. Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. The Unity and Diversity of Executive Functions and their contributions to Complex Frontal Lobe Tasks: a latent variable analysis. *Cogn Psychol*. 2000;41(1):49–100.
42. Delis DC, Kaplan E, Kramer J. Delis Kaplan executive function system (D-KEFS). San Antonio, TX: Pearson Psychological Corporation; 2001.
43. Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. *Biol Psychiatry*. 2005;57(6):688–91.
44. Beck AT, Steer RA, Brown G. Beck Depression Inventory–II (BDI-II). Psychological assessment; 1996.
45. Cohen J. Statistical power analysis for the behavioral Sciences. New York, NY: Routledge; 1988.
46. Thompson B. What future quantitative Social Science Research could look like: confidence intervals for Effect Sizes. *Educational Researcher*. 2002;31(3):25–32.
47. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. *Biol Rev*. 2007;82:591–605.
48. Benjamini Y, Hochberg Y. Controlling the false Discovery Rate - a practical and powerful Approach to multiple testing. *J Roy Stat Soc: Ser B (Methodol)*. 1995;57(1):289–300.
49. Wickham H. *Elegant graphics for data analysis*. New York, NY: Springer-Verlag; 2016.
50. Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. *Soc Sci Med*. 1999;9:77–88.
51. Berry SA, Brown C, Grant M, Greene CL, Jurecki E, Koch J et al. Newborn screening 50 years later: Access issues faced by adults with PKU. Vol. 15, *Genetics in Medicine*. 2013. p. 591–9.

52. Beghini M, Resch FJ, Möslinger D, Konstantopoulou V, Karall D, Scholl-Bürgi S, et al. Project Backtoclinic I: an overview on the state of care of adult PKU patients in Austria. *Mol Genet Metab*. 2021;133(3):257–60.
53. Ney DM, Gleason ST, van Calcar SC, MacLeod EL, Nelson KL, Etzel MR, et al. Nutritional management of PKU with glycomacropeptide from cheese whey. *J Inherit Metab Dis*. 2009;32(1):32–9.
54. Daly A, Evans S, Pinto A, Ashmore C, Macdonald A. Protein substitutes in PKU; their historical evolution. *Nutrients*. 2021;13:1–15.
55. Cazzorla C, Bensi G, Biasucci G, Leuzzi V, Manti F, Musumeci A, et al. Living with phenylketonuria in adulthood: the PKU ATTITUDE study. *Mol Genet Metab Rep*. 2018;16:39–45.
56. Burgard P, Ullrich K, Ballhausen D, Hennermann JB, Hollak CEM, Langeveld M, et al. Issues with european guidelines for phenylketonuria. *Lancet Diabetes Endocrinol*. 2017;5(9):681–3.
57. Smith I, Knowles J. Behaviour in early treated phenylketonuria: a systematic review. *Eur J Pediatr*. 2000;159:89–93.
58. Brown CS, Lichter-Konecki U. Phenylketonuria (PKU): a problem solved? *Mol Genet Metab Rep*. 2018;16:39–45.
59. Bardage C, Isacson DGL. Hypertension and health-related quality of life: an epidemiological study in Sweden. *J Clin Epidemiol*. 2001;54:172–81.
60. Mrus JM, Williams PL, Tsevat J, Cohn SE, Wu AW. Gender differences in health-related quality of life in patients with HIV/AIDS. *Qual Life Res*. 2005;14:479–91.
61. Gijbels CM, Agostoni P, Hofer IE, Asselbergs FW, Pasterkamp G, Nathoe H, et al. Gender differences in health-related quality of life in patients undergoing coronary angiography. *Open Heart*. 2015;2(1):e000231.
62. Van Jaarsveld CHM, Sanderman R, Ranchor AV, Ormel J, Van Veldhuisen DJ, Kempen GJM. Gender-specific changes in quality of life following cardiovascular disease: a prospective study. *J Clin Epidemiol*. 2002;55(11):1105–12.
63. Heller J, Dogan I, Schulz JB, Reetz K. Evidence for gender differences in cognition, emotion and quality of life in parkinson's disease? *Aging and Disease*. Volume 5. International Society on Aging and Disease; 2014. pp. 63–75.
64. Kaplan RM, Anderson JP, Wingard DL. Gender differences in health-related quality of life. *Health Psychol*. 1991;10(2):86–93.
65. Gil-Lacruz M, Gil-Lacruz AI. Health Perception and Health Care Access: sex differences in behaviors and attitudes. *Am J Econ Sociol*. 2010;69(2):783–801.
66. Barsky AJ, Peekna HM, Borus JF. Somatic Symptom reporting in women and men. *J Gen Intern Med*. 2001;16(4):266–75.
67. Ford S, O'Driscoll M, MacDonald A. Reproductive experience of women living with phenylketonuria. *Mol Genet Metab Rep*. 2018;17:64–8.
68. Cherepanov D, Palta M, Fryback DG, Robert SA. Gender differences in health-related quality-of-life are partly explained by sociodemographic and socioeconomic variation between adult men and women in the US: evidence from four US nationally representative data sets. *Qual Life Res*. 2010;19(8):1115–24.
69. Hollingshead AB. Four factor index of social status. 1975.
70. Salekin RT, Lee Z, Schrum Dillard CL, Kubak FA. Child psychopathy and protective factors: IQ and motivation to change. *Psychol Public Policy Law*. 2010;16(2):158–76.
71. Waisbren SE, Noel K, Fahrback K, Cella C, Frame D, Dorenbaum A, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. *Mol Genet Metab*. 2007;92(1–2):63–70.
72. Fannesbeck CJ, McPheeters ML, Krishnaswami S, Lindgren ML, Reimschisel T. Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis. *J Inherit Metab Dis*. 2013;36(5):757–66.
73. Canuet L, Ishii R, Iwase M, Ikezawa K, Kurimoto R, Azechi M, et al. Factors associated with impaired quality of life in younger and older adults with epilepsy. *Epilepsy Res*. 2009;83(1):58–65.
74. Ay-Woan P, Sarah CPY, Lynn C, Tsyng-Jang C, Ping-Chuan H. Quality of life in depression: predictive models. *Qual Life Res*. 2006;15(1):39–48.
75. Lee HJ, Chapa D, Kao CW, Jones D, Kapustin J, Smith J, et al. Depression, quality of life, and glycemic control in individuals with type 2 diabetes. *J Am Acad Nurse Pract*. 2009;21(4):214–24.
76. Schraegle WA, Titus JB. Executive function and health-related quality of life in pediatric epilepsy. *Epilepsy and Behavior*. 2016;62:20–6.
77. Cotrena C, Branco LD, Shansis FM, Fonseca RP. Executive function impairments in depression and bipolar disorder: Association with functional impairment and quality of life. *J Affect Disord*. 2016;190:744–53.
78. Rindermann H. The g-factor of international cognitive ability comparisons: the homogeneity of results in PISA, TIMSS, PIRLS and IQ-tests across nations. *Eur J Pers*. 2007;21(5):667–706.
79. Jahja R, van Spronsen FJ, de Sonnevill LMJ, van der Meere JJ, Bosch AM, Hollak CEM, et al. Long-term Follow-Up of Cognition and Mental Health in Adult Phenylketonuria: a PKU-COBESO study. *Behav Genet*. 2017;47(5):486–97.
80. Quinn J, Georgiadis A, Lewis HB, Jurecki E. Measuring Burden of Illness in Phenylketonuria (PKU): development of the PKU Symptom Severity and Impacts Scale as a robust patient-reported outcome. *Adv Ther*. 2022;39(2):971–91.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.